S. Ohshimo (Hiroshima, Japan), M. Funke-Chambour (Bern, Switzerland)
Biomarkers of collagen formation are predictive of IPF progression and death
N. Hoyer (Copenhagen, Denmark), H. Jessen (Herlev, Denmark), S. Rønnow (Herlev, Denmark), M. Karsdal (Herlev, Denmark), D. Leeming (Herlev, Denmark), J. Sand (Herlev, Denmark), S. Shaker (Copenhagen, Denmark)
|     |
Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial
G. Jenkins (Nottingham, United Kingdom), I. Noth (Charlottesville, Virginia, United States of America), M. Selman (Mexico City, Mexico), V. Cottin (Lyon, France), Y. Nishioka (Tokushima, Japan), J. Song (Seoul, Republic of Korea), A. Prasse (Hannover, Germany), E. White (Ann Arbor, Michigan, United States of America), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein,, Germany), S. Stowasser (Ingelheim am Rhein,, Germany), T. Maher (London, United Kingdom)
| |
Association of neoepitopes with disease severity and respiratory hospitalization in patients with IPF
J. Oldham (Sacramento, California, United States of America), J. Todd (Durham, North Carolina, United States of America), M. Neely (Durham, North Carolina, United States of America), H. Mulder (Durham, North Carolina, United States of America), R. Overton (Durham, North Carolina, United States of America), H. Kim (Minneapolis, Minnesota, United States of America), M. Gulati (New Haven, Connecticut, United States of America), T. Leonard (Ridgefield, Connecticut, United States of America), S. Palmer (Durham, North Carolina, United States of America), I. Noth (Charlottesville, Virginia, United States of America), C. Hesslinger (Biberach, Germany)
| |
Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial
E. White (Ann Arbor, Michigan, United States of America), V. Cottin (Lyon, France), M. Kolb (Hamilton, Ontario, Canada), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France)
| |
Prognostic value of oxygenated hemoglobin (OxyHem) in fibrosing interstitial lung diseases
S. Torrisi (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), K. Höger (Heidelberg, Germany), F. Wilkens (Heidelberg, Germany), R. Jörres (Munich, Germany), F. Trudzinski (Heidelberg, Germany)
| |
Diagnosis of interstitial lung diseases using eNose technology
C. Moor (Rotterdam, Netherlands), J. Oppenheimer (Rotterdam, Netherlands), G. Nakshbandi (Rotterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), P. Brinkman (Amsterdam, Netherlands), A. Maitland- Van Der Zee (Amsterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
| |
Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis
K. Yamaguchi (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), W. Mazur (Helsinki, Finland), S. Miura (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), Y. Horimasu (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Ohshimo (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Hattori (Hiroshima, Japan)
| |